Navigation Links
Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Date:6/25/2008

TSX Venture: QPT

EDMONTON, June 25 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or the "Company"), today announced interim results from its Phase I/II clinical study designed to investigate appropriate treatment parameters for the potential use of its proprietary compound SL017 for hair removal applications. The interim results represent data from the first 80 patients enrolled in the targeted 100-patient clinical trial.

"The Phase I/II interim results demonstrated that SL017 is safe and well tolerated when used either alone or in combination with photo activation," said Madi Madiyalakan, Chief Executive Officer of Quest. "These results, along with results from the previous clinical trial, support the utility of SL017 for hair removal applications, especially for those who do not benefit from light treatment alone."

To permanently remove unwanted hair, existing laser hair removal techniques require four to eight treatments, and provide only a 75 to 85 percent permanent hair reduction in a limited patient population. The professional laser hair removal market is estimated to be $5 billion worldwide.

Quest is developing SL017 photodynamic therapy (PDT) as a potential hair removal solution that is effective across a broad patient population including those with light colored hair (for example, grey or blonde hair). In a Phase I clinical trial, Quest demonstrated the preferential localization of SL017 in hair follicles, which suggested that cutaneous PDT with SL017 has potential for permanent hair removal applications.

The Phase I/II trial of SL017 was designed to evaluate the effect of skin treatment on follicular uptake of SL017, assess the tolerable light dose on healthy subjects, and subsequently, determine the efficacy of hair removal under optimal treatment conditions. Results from this study will be used to guide the design of future clinical development.

Skin Pret
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 29, 2014 Global polyvinyl chloride ... world economic crisis during 2008-2009, especially in North America ... and currently is keeping to a growing trend. , ... is utilized in the construction segment. In 2013, the ... profiles, tubing, sheets and rigid film. Moreover, the PVC ...
(Date:10/30/2014)... 30, 2014 Rancho BioSciences , ... have manually curated public data source TCGA ... the data is now available for other oncology ... public and internal data sources for their Pharma, Government ... of the data that becomes more easily accessible. ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success ... of its fleet of high volume High Pressure Processing (HPP) ... we return to PackExpo this year, which is where we ... said Jeff Williams, CEO at Avure. “Sales of the new ... be meeting the challenges of market demand for higher throughput. ...
(Date:10/30/2014)... N.J. , Oct. 30, 2014  Regado Biosciences, ... it will hold a conference call and live audio ... EST to discuss its third quarter 2014 financial results. ... conference call by dialing (888) 347-1165 for domestic callers ... will be webcast live under the investor relations section ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... LA JOLLA, Calif., Oct. 29 Immunosyn,Corporation (OTC ... G.,David Criner as the company,s Chief Financial and ... Douglas A.,McCain, Jr., has been appointed as the ... position as Corporate Secretary. "I believe that ...
... Md., Oct. 29 /PRNewswire/,-- Cambridge Antibody Technology ... to,reflect AstraZeneca,s vision for its worldwide biologics ... resources and expertise from CAT, the pre-,existing ... AstraZeneca,Group, under the "MedImmune" name. With this ...
... Ltd., the Innovator in,Ultrasound for more than 50 years, ... platforms for advanced cardiac and,vascular imaging, the ProSound Alpha ... of American Heart Association, at the Orange County,Convention Center ... Alpha 7 and the Alpha 10 incorporate all of ...
Cached Biology Technology:Immunosyn Corporation Names G. David Criner as CFO 2AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 3
(Date:10/29/2014)... living world compete with members of their own ... they invest into their competitive ability. Some individuals ... to high-quality resources, while others seem to avoid ... resources that are left over for them. Moreover, ... societies seems to fluctuate considerably over time. A ...
(Date:10/29/2014)... kidney cancer patients in Europe sheds light on the ... apparent link between exposure to aristolochic acid and incidence ... by an international team led by scientists from the ... underscores the importance of investigating possible sources of exposure ... the Aristolochia genus, also has been suspected of causing ...
(Date:10/28/2014)... have published a paper in the Proceedings of ... details about key transitions in the evolution of plant ... mosses, ferns, trees and flowers growing deep in steamy ... the ornamental plants adorning our homes, all plant life ... "Our study generated DNA sequences from a vast number ...
Breaking Biology News(10 mins):Evolution of competitiveness 2Evolution of competitiveness 3Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3
... The Aplastic Anemia & MDS International Foundation (AA&MDSIF) ... & Drug Administration (FDA) has expanded the label for ... which found that Vidaza is the only agent that ... also shown to delay progression to acute myelogenous leukemia ...
... in German . , Bremerhaven, August 19th ... Wegener Institute for Polar and Marine Research in the ... time. Polarstern left the port of Reykjavik on August ... is located right in the Northwest Passage. Its destination ...
... 21, 2008) The leading figures in ... exciting breakthroughs in this revolutionary field of research at ... Translational Stem Cell Research Conference, October 14-15 at The ... on the dramatic advancements researchers are making in developing ...
Cached Biology News:RV Polarstern on its way to East Siberian Sea 2RV Polarstern on its way to East Siberian Sea 3New York Stem Cell Foundation announces third annual Translational Stem Cell Research Conference 2New York Stem Cell Foundation announces third annual Translational Stem Cell Research Conference 3
See product name for description....
... 20 Amino Acid length max , MS-spec check ... customer for future usage conjugation of peptide to KLH protein , ... days/each , Pre-immune bleed x1 /each ... Test bleed (app. 5 ml) x1 /each , ...
... following: , Coated Capture Antibody: 12 x 8-well ... 300 mL of 2X concentrate , Beta ... peptide , Lyophilized Standard Diluent: 3 mL , ... Secondary Antibody-HRP: 30 microL of concentrate , OPD ...
Human Cell Line Slides...
Biology Products: